Subscribe

Rectal Cancer

First-Line Treatment with Dostarlimab Led to Remission in All Patients with Mismatch Repair-Deficient Rectal Cancer
By Patricia Stewart
Rectal Cancer
TON - August 2022 Vol 15, No 4
First-line treatment with dostarlimab-gxly (Jemperli), a PD-1 inhibitor, achieved complete responses (CRs) in 100% of a subset of patients with locally advanced mismatch repair-deficient (dMMR) rectal cancer, sparing them surgery, chemotherapy, and radiation, as of the latest follow-up. Read More ›


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, monthly TON print publication and TON weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.